Newton Charles W., CFO of Lyell Immunopharma ($LYEL), bought shares once on the open market in the last year, totaling about $112 thousand, with the latest purchase on March 17, 2025. This ranks him 2,045th among 4,983 insiders by purchase value, well below the average of $1.5 million across 3.3 transactions. He sold shares three times for about $18 thousand total, most recently on August 21, 2025, ranking 11,082nd out of 11,678 insiders, far under the average $8.6 million across 6.4 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Keros Therapeutics, Inc. | $KROS | Newton Charles W. | Not found | A | Common Stock | 13215 | $0.00 | 13,215.0000 | 41,202,371 | 9999.99% | 0.03% |
| March 9, 2026 | Keros Therapeutics, Inc. | $KROS | Newton Charles W. | Not found | A | Stock Option (Right to Buy) | 14788 | $0.00 | 14,788.0000 | 41,202,371 | 9999.99% | 0.04% |
| Aug. 20, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Common Stock | 8000 | $0.00 | 26,759.0000 | 295,228,868 | 42.65% | 0.00% |
| Aug. 21, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | S | Common Stock | 1453 | $10.54 | 25,306.0000 | 295,228,868 | 5.43% | 0.00% |
| Aug. 12, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | S | Common Stock | 136 | $10.34 | 18,759.0000 | 295,228,868 | 0.72% | 0.00% |
| Aug. 11, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | S | Common Stock | 131 | $10.53 | 18,895.0000 | 295,228,868 | 0.69% | 0.00% |
| June 12, 2025 | Coherus Oncology, Inc. | $CHRS | Newton Charles W. | Not found | A | Stock Option (Right to Buy) | 112000 | $0.00 | 112,000.0000 | 115,857,780 | 9999.99% | 0.10% |
| April 25, 2025 | NOVAVAX INC | $NVAX | Newton Charles W. | Director | A | Restricted Stock Units | 28560 | $0.00 | 28,560.0000 | 152,190,000 | 9999.99% | 0.02% |
| April 25, 2025 | NOVAVAX INC | $NVAX | Newton Charles W. | Director | A | Stock Option (Right to buy) | 42840 | $0.00 | 42,840.0000 | 152,190,000 | 9999.99% | 0.03% |
| March 17, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | P | Common Stock | 200000 | $0.56 | 372,725.0000 | 295,228,868 | 115.79% | 0.07% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Option (right to buy) | 56250 | $0.00 | 56,250.0000 | 0 | 9999.99% | 0.00% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Common Stock | 112500 | $0.00 | 172,725.0000 | 0 | 186.80% | 0.00% |
| Feb. 10, 2025 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Option (right to buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| June 3, 2024 | Coherus Oncology, Inc. | $CHRS | Newton Charles W. | Not found | A | Stock Option (Right to Buy) | 112000 | $0.00 | 112,000.0000 | 112,749,306 | 9999.99% | 0.10% |
| Feb. 9, 2024 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Common Stock | 40000 | $0.00 | 48,729.0000 | 0 | 458.24% | 0.00% |
| Feb. 9, 2024 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Stock Option (right to buy) | 400000 | $0.00 | 400,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | D | Stock Option (right to buy) | 3612000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | D | Stock Option (right to buy) | 190000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Stock Option (right to buy) | 516000 | $0.00 | 516,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | D | Stock Option (right to buy) | 516000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Stock Option (right to buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | D | Stock Option (right to buy) | 500000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Stock Option (right to buy) | 190000 | $0.00 | 190,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 16, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Stock Option (right to buy) | 3612000 | $0.00 | 3,612,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 24, 2023 | Lyell Immunopharma, Inc. | $LYEL | Newton Charles W. | Chief Financial Officer | A | Option (right to buy) | 700000 | $0.00 | 700,000.0000 | 0 | 9999.99% | 0.00% |